Hypercholesterolemia

Long-Term Evolocumab Safe and Effective for Treating Hypercholesterolemia

Long-Term Evolocumab Safe and Effective for Treating Hypercholesterolemia

By

Evolocumab consistently reduced LDL-C with no increase in adverse events over a 5-year study period.

Nonadherence, Discontinuation High in First Year of Statin Therapy

Nonadherence, Discontinuation High in First Year of Statin Therapy

First-year nonadherence and discontinuation are high among older adults prescribed statins.

Statin-Induced Musculoskeletal AEs and Timing of Concurrent Treatment Examined

Statin-Induced Musculoskeletal AEs and Timing of Concurrent Treatment Examined

By

The data showed MAEs onset was significantly faster with atorvastatin and rosuvastatin compared with simvastatin; a comparison with other statins could not be established due to the small number of cases identified.

Lack of Evidence for Noncardiovascular Outcomes With Statin Use

Lack of Evidence for Noncardiovascular Outcomes With Statin Use

There is a lack of convincing evidence for an association between statin use and noncardiovascular disease outcomes.

Statin-Induced Myalgia Unrelated to Muscle Coenzyme Q10 Level

Statin-Induced Myalgia Unrelated to Muscle Coenzyme Q10 Level

By

Statin therapy is associated with reduced mitochondrial complex II-linked respiration, and statin-induced myalgia is coupled to an increased intrinsic mitochondrial respiratory function, while intramuscular [coenzyme Q10] levels are unaltered.

Intensive LDL-C lowering reduces mortality in patients with higher baseline LDL-C

In this systematic review and meta-analysis, more intensive compared with less itensive LDL-C lowering was associated with a greater reduction in risk of total and cardiovascular mortality in trials of patients with higher baseline LDL-C levels.

How Low is Too Low?: Safety and Tolerability of Extremely Low LDL Examined

How Low is Too Low?: Safety and Tolerability of Extremely Low LDL Examined

By

Data from 14 phase 2 and 3 studies were pooled to assess the safety of lowering LDL cholesterol with alirocumab.

Combination Ezetimibe/Rosuvastatin Beats Rosuvastatin Alone in Hypercholesterolemia

Combination Ezetimibe/Rosuvastatin Beats Rosuvastatin Alone in Hypercholesterolemia

For patients with primary hypercholesterolemia, fixed-dose combination of ezetimibe plus rosuvastatin is more effective than rosuvastatin alone.

Study Indicates PCSK9 Inhibitor Use Is Not Cost-Effective

Study Indicates PCSK9 Inhibitor Use Is Not Cost-Effective

For patients with familial hypercholesterolemia or atherosclerotic cardiovascular disease, PCSK9 inhibitor use is not cost-effective.

FDA Approves Single Monthly Injection of PCSK9 Inhibitor

FDA Approves Single Monthly Injection of PCSK9 Inhibitor

By

Evolocumab will now be available via the Pushtronex systemâ„¢, designed to deliver 420 mg in a single dose.

Familial Hypercholesterolemia Tied to Significantly Increased CVD Risk

Familial Hypercholesterolemia Tied to Significantly Increased CVD Risk

Patients with heterozygous familial hypercholesterolemia have a significantly increased risk for coronary heart disease and atherosclerotic cardiovascular disease.

More People May Have Inherited Cholesterol Condition Than Previously Thought

More People May Have Inherited Cholesterol Condition Than Previously Thought

Researchers found that roughly 834 500 Americans have the inherited condition.

ACA Ups Diagnosis, Treatment of Chronic Diseases

ACA Ups Diagnosis, Treatment of Chronic Diseases

Higher numbers of insured leading to more treatment of hypertension, high cholesterol and diabetes.

FDA Approves Alirocumab for Certain Patients With High Cholesterol

FDA Approves Alirocumab for Certain Patients With High Cholesterol

By

The FDA has approved the first PCSK9 inhibitor to treat certain adults with high cholesterol.

FDA Panel Favors Approval of Alirocumab for Hypercholesterolemia

FDA Panel Favors Approval of Alirocumab for Hypercholesterolemia

By

An FDA advisory committee has recommended approval of alirocumab (Praluent, Regeneron) for treatment of hypercholesterolemia.

OSLER: Evolocumab May Lower LDL Cholesterol in Long Term

OSLER: Evolocumab May Lower LDL Cholesterol in Long Term

By

The PCSK9 inhibitor evolocumab appears to be safe and effective for reducing LDL cholesterol in older patients.

Moderate Lipid Changes in Rheumatoid Arthritis With Tocilizumab/Tofacitinib

Moderate Lipid Changes in Rheumatoid Arthritis With Tocilizumab/Tofacitinib

Review shows no changes for rheumatoid arthritis patients with tumor necrosis factor antagonist treatment.

Evolocumab Highly Effective for Familial Hypercholesterolemia

Evolocumab Highly Effective for Familial Hypercholesterolemia

Two studies show that PCSK9 inhibition lowered LDL cholesterol in heterozygous and homozygous familial hypercholesterolemia.

Long-Term Statins Beneficial in Familial Hypercholesterolemia

Long-Term Statins Beneficial in Familial Hypercholesterolemia

Long-term statin use among children with familial hypercholesterolemia is associated with normalization of carotid intima-media thickness progression.

Alirocumab Effective in Hypercholesterolemia Trials

Alirocumab Effective in Hypercholesterolemia Trials

Sanofi and Regeneron announced positive results from four phase 3 ODYSSEY trials of alirocumab in patients with hypercholesterolemia.

Biologics Licensing Application for Evolocumab Submitted to FDA

Amgen announced that it has submitted a Biologics License Application (BLA) to the Food and Drug Administration (FDA) for evolocumab for the treatment of high cholesterol.

Traditional CVD Risk Factors Hit Women, Blacks Harder

Traditional CVD Risk Factors Hit Women, Blacks Harder

Cutting traditional risk factors could eliminate significant amount of cardiovascular disease

Sign Up for Free e-Newsletters



CME Focus